Alk-Abello ASWBO:ALKB -0.12%65 Current Ratio is 3.25 as of Mar. 2026, which is 39% above its 10-year median of 2.34. GuruFocus rates WBO:ALKB with a GF Score™ of 65/100 and a GF Value™ of €27.26 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Alk-Abello AS ranks worse than 55.51% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Alk-Abello AS's current ratio for the quarter that ended in Mar. 2026 was 3.25.
Alk-Abello AS has a current ratio of 3.25. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Alk-Abello AS's Current Ratio or its related term are showing as below:
WBO:ALKB'
s Current Ratio Range Over the Past 10 Years
Min: 1.66 Med: 2.34 Max: 3.38
Current: 3.25
During the past 13 years, Alk-Abello AS's highest Current Ratio was 3.38. The lowest was 1.66. And the median was 2.34.
WBO:ALKB's Current Ratio is ranked worse than 55.51% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs WBO:ALKB: 3.25
Alk-Abello AS (WBO:ALKB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Alk-Abello AS Current Ratio Related Terms
Alk-Abello AS Current Ratio Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:ALKB vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Alk-Abello AS's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Current Ratio distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (WBO:ALKB) has a Current Ratio of 3.25 as of Mar. 2026. This is 39% above median its historical median of 2.34. Over the past decade, Alk-Abello AS's Current Ratio has ranged from 1.66 to 3.38. According to the industry distribution chart, Alk-Abello AS ranks #786 out of 1416 companies in the Biotechnology industry, placing it in the top 55.5%.
Is Alk-Abello AS's Current Ratio too high?
Alk-Abello AS's current Current Ratio of 3.25 is 39% above median its 10-year median of 2.34. Over the past 10 years, this metric has ranged from a low of 1.66 to a high of 3.38. The Biotechnology industry median Current Ratio is 3.89. Alk-Abello AS's value of 3.25 is 16.3% below this industry median. Based on the distribution chart, Alk-Abello AS ranks #786 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alk-Abello AS has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #786 out of 1416 companies for Current Ratio. This places Alk-Abello AS in the lower half of its industry. The industry median Current Ratio is 3.89. Alk-Abello AS's value of 3.25 is 16.3% below this benchmark. Historically, Alk-Abello AS's own Current Ratio has ranged from 1.66 to 3.38 over the past decade. While the company's 10-year median is 2.34 vs. the industry median of 3.89, Alk-Abello AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current Current Ratio of 3.25 is 16.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current Current Ratio is 3.25, which is 39% above median its own 10-year median of 2.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (WBO:ALKB) is currently considered Modestly Overvalued. The stock's GF Value™ is €27.26, compared to a current price of €34.22 — trading 25.5% above its estimated fair value. The current Current Ratio is 3.25, which is 39% above median its 10-year median of 2.34 and 16.3% below the Biotechnology industry median of 3.89. Alk-Abello AS's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Alk-Abello AS (WBO:ALKB), the current Current Ratio is 3.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (WBO:ALKB) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of €34.22 is trading 25.5% above its estimated GF Value™ of €27.26.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for WBO:ALKB:
Current Ratio: 3.25 (39% above median its 10-year median of 2.34)
GF Value™: €27.26 vs. price of €34.22 (25.5% above fair value)
Industry Position: 16.3% below the Biotechnology median (#786 of 1416)
No single metric tells the full story. See the WBO:ALKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
65GF Score
Get the complete analysis for WBO:ALKB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ALKB has been successfully added to your 
